Drug intelligence / Profile preview

toripalimab + carboplatin + nab-paclitaxel

Development stage: Unknown
Lead developer: Junshi Biosciences
Modality: Nanoparticles → Drug Delivery Systems, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

This combination therapy is a neoadjuvant regimen consisting of the PD-1 inhibitor toripalimab, the platinum-based chemotherapy carboplatin, and the albumin-bound microtubule inhibitor nab-paclitaxel. It is currently being investigated in Phase II clinical trials by Sun Yat-Sen Memorial Hospital for the treatment of resectable salivary gland malignant neoplasms. Toripalimab, developed by Shanghai Junshi Bioscience, is a humanized IgG4 monoclonal antibody that blocks the interaction between PD-1 and its ligands (PD-L1 and PD-L2), thereby restoring T-cell mediated anti-tumor immunity. Carboplatin induces cell death by creating interstrand DNA cross-links, while nab-paclitaxel inhibits mitosis by stabilizing microtubules. The combination aims to reduce tumor size and improve surgical outcomes through synergistic immune activation and cytotoxic effects.

Brand names: TuoyiAbraxane
Other names: Toripalimab + Carboplatin + Nab-paclitaxelToripalimab plus chemotherapy

Targets

PDCD1 (Programmed cell death protein 1 receptor)TUBB (Tubulin (alpha and beta subunits))DNA

Beyond the preview

Go deeper on toripalimab + carboplatin + nab-paclitaxel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on toripalimab + carboplatin + nab-paclitaxel.

Explore the full profile